

COLLABORATIVE ILD CARE:

Building Community in
PULMONOLOGY AND RHEUMATOLOGY

Table of Contents

Final Outcomes Summary

- Executive Summary: Slide 3
- Program Features: Slide 4
- Faculty: Slides 5-6
- Audience Generation: Slide 7
- Learner Definitions and Guarantees: Slide 8
- Overall Program Participation: Slide 9
- Video Module Outcomes: Slides 10-26
 - Video Module Level 1 (Participation): Slides 11-12
 - Video Module Level 2 (Satisfaction): Slide 13
 - Video Module Level 3&4 (Knowledge and Competence): Slides 14-26
 - Video Module Level 4 (Competence): Slide 27
- Live Virtual Meeting Outcomes: Slides 28-36
 - Live Virtual Meetings Level 1 (Participation): Slide 30
 - Live Virtual Meetings Level 2 (Satisfaction): Slide 31
 - Live Virtual Meetings Level 3&4 (Knowledge and Competence): Slides 32 – 35
 - Live Virtual Meetings Level 4 (Competence): Slide 36
- Community Forum Overview: Slide 37
- Level 5 Outcomes (Performance): Slides 38-40
- Evaluation Survey Results: Slide 41
- Program Insights: Slide 42
- Accreditation: Slide 43

Executive Summary

Final Outcomes Summary

Program Chairs



Zulma X. Yunt, MD

Associate Professor
Department of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
Clinic Director, Interstitial Lung Disease Program
Medical Director, Office of Professional Education
National Jewish Health



Barbara Goldstein, MD, MMSc

Physician
Denver Arthritis Clinic

Program Overview

This 10-month pilot program engaged community-based and academic rheumatologists and pulmonologists by fostering a community of practice focused on early diagnosis, evidence-based treatment, and multidisciplinary collaboration to improve care for patients with interstitial lung disease (ILD). The program featured 9 online video modules, 4 case-based live-virtual meetings, and an expert-facilitated community forum, fostering collaboration, knowledge retention, and professional networking.

Learning Objectives

1. Describe the pathophysiology and classification of ILD.
2. Recognize signs, symptoms, and risk factors for ILD.
3. Apply evidence-based diagnostic strategies to provide timely and accurate diagnosis of ILD.
4. Implement multidisciplinary approaches for the early identification of and treatment of ILD.
5. Apply up-to-date guidelines for the treatment of ILD.
6. Evaluate current and emerging approaches for ILD treatment.

Target Audience & Accreditation

Target Audience: Rheumatologists, pulmonologists and advanced practice providers who may care for patients with ILD.

Accreditation

National Jewish Health designates the activities for up to 10.0 *AMA PRA Category 1 Credits*™ and 10.0 ABIM MOC points. Learners may only claim credit for the portion of the activity they completed.

Program Formats and Timeline:

Video Modules: 6/30/2025 – 3/31/2026

Community Forum: 7/31/2025 – 3/31/2026

Live Virtual Meetings: 8/27/2025, 10/30/2025, 1/13/2025, 3/10/2026

Program Features

Final Outcomes Summary

OVERALL PROGRAM GOAL

To build community and collaboration between academic and community clinicians and between rheumatologists and pulmonologists to improve ILD care



Educational Video Modules: Covering ILD pathophysiology, diagnostic testing, and treatment advances, these modules ensure a strong foundation for all participants.



Live Virtual Case-Based Meetings: Facilitated by academic experts and community practitioners, these interactive sessions provide real-world insights, foster trust, and encourage the application of updated guidelines.



Community Conversation Boards: A platform for ongoing peer-to-peer engagement, case discussion, and knowledge sharing.

“This program was a great way to connect community physicians with academicians and have an open discussion about the approaches to patients with rheumatic disease and ILD. The forum was a way to connect and interact openly and honestly with great feedback and thoughts on cases. I personally enjoyed updating my knowledge base on therapeutics and approaches.”

– Barbara Goldstein, MD, Program Chair

Program Faculty

Final Outcomes Summary



Vivianne Allsop, MD
Clinical Instructor
Division of Rheumatology
Department of Medicine
National Jewish Health



Melissa Griffith, MD
Associate Professor,
Medicine-Rheumatology
University of Colorado



Mehrnaz Maleki Fischbach, MD
Chief, Division of Rheumatology
Director, Scleroderma Center
Co-Director, Sjogren's Clinic
Professor
Department of Medicine
National Jewish Health



Rebecca Keith, MD
Associate Professor
Department of Medicine
Division of Pulmonary, Critical
Care & Sleep Medicine
Interstitial Lung Disease
Program
Autoimmune Lung Center
National Jewish Health

Program Faculty

Final Outcomes Summary



Ivana Ilic, MD
Clinical Instructor
Division of Rheumatology
Department of Medicine
National Jewish Health



Kevin Rurak, MD,
Assistant Professor
Division of Pulmonary,
Critical Care & Sleep
Medicine
Department of Medicine
National Jewish Health



Smarika Sapkota, MD
Assistant Professor
Department of
Medicine
Division of
Rheumatology
National Jewish Health



Josh Solomon, MD
Director, Interstitial Lung
Disease Program
Professor
Department of Medicine
Division of Pulmonary,
Critical Care & Sleep
Medicine
Section of Critical Care
Medicine
National Jewish Health



Jeff Swigris, MD
Professor
Department of Medicine
Division of Pulmonary,
Critical Care & Sleep
Medicine
National Jewish Health

Audience Generation


Final Outcomes Summary

Personalized emails sent to National Jewish Health faculty and provider databases



Emails to purchased lists of pulmonologists and rheumatologists

Flyer distributed to providers' offices



Module videos promoted on Vumedi website

Social media ads and posts



Live virtual meetings promoted on FreeCME website and emailed to targeted audiences

Learner Definitions and Guarantees


Final Outcomes Summary

Category	Definition	Guarantees	Actuals
Overall Program Participant	Registered on the Collaborative ILD Care program website and/or participated in one or more program components	80 physicians	176 physician participants 274 total participants
Online Enduring Learner	Participated in at least one video module	N/A	53 physician learners 69 total learners
Live Virtual Meeting Learner	Attended one or more of the live virtual meetings	N/A	74 physician learners 121 total learners
Certificate	Passed the post-test, completed the evaluation and claimed credit on the Collaborative ILD Care program website (for any component of the program)	N/A	111 total certificates

Overall Program Participation

Final Outcomes Summary

Degree




MD/DO=176
NP=16
PA=16
RN=28
PharmD=6
Other HCP=19
Other=13
Total Participants=274

76% of participants are physicians and APPs

Note: While we originally proposed a maximum of 80 learners in the program, we allowed more participation because we found that most learners were not participating in every component of the program. We increased the overall program participation beyond the maximum to ensure that each of the online modules, live virtual meetings, and community forum has robust participation and engagement.


Specialty



Pulmonology=149
Rheumatology=34
Internal Medicine=10
Family Medicine/General Practice=21
Other=60
Total Participants=274

67% of participants are in pulmonology and rheumatology

Practice Setting



Academic Medical Center=54
Community Hospital=36
Private Practice=38
Other=25
Not reported=121
Total Participants=274

Online Modules: Overview

Final Outcomes Summary

Online Modules Released June 30, 2025

1. Introduction to Interstitial Lung Disease (ILD) – 0.25 Credits
2. Progressive Pulmonary Fibrosis – 0.25 Credits
3. Recognizing SARD-ILD: Diagnosis and Screening – 0.75 Credits
4. Pharmacologic Treatment of SARD-ILD:
Lung-Targeted Immunomodulatory and Anti-Fibrotic Therapy – 0.5 Credits
5. Multidisciplinary Medication Management in ILD Care – 0.5 Credits
6. Non-Pharmacologic Approaches to ILD Management – 0.25 Credits
7. Comorbidities of SARD-ILD – 0.25 Credits
8. Pulmonary Hypertension in Rheumatologic Disease – 0.25 Credits
9. Strategies for Multidisciplinary Collaboration in ILD Care – 0.25 Credits

Available Modules

These self-paced video modules will provide a foundation in ILD classification, diagnosis, treatment, and multidisciplinary care. As a participant in this program, you have access to all video module content but can choose to view the modules most relevant to your practice. CME/MOC credit is based on participation and will be awarded for each module individually. Please refer to the accreditation information within each module for more information.



Introduction to Interstitial Lung Disease (ILD)
Credits: 0.25 CME

In this module, we discuss ILD pathophysiology and classification, clinical signs and symptoms of ILD, and how to recognize and evaluate patients presenting with suspected ILD.



Progressive Pulmonary Fibrosis
Credits: 0.25 CME

In this module, we explore the pathophysiology and radiologic features of progressive pulmonary fibrosis, as well as strategies for identifying and monitoring progression in patients with ILD.



Recognizing SARD-ILD: Diagnosis and Screening
Credits: 0.75 CME

In this module, we review clinical presentation and symptoms of systemic auto-immune rheumatic disease-associated ILD (SARD-ILD), as well as best practices for diagnosis and screening of SARD-ILD in pulmonary and rheumatology clinic settings.



Pharmacologic Treatment of SARD-ILD: Lung-Targeted Immunomodulatory and Anti-Fibrotic Therapy
Credits: 0.50 CME

In this module, we hear from a pulmonologist and rheumatologist on current and emerging anti-fibrotic and anti-rheumatic treatment options for systemic auto-immune rheumatic disease-associated ILD (SARD-ILD). We will discuss mechanism of action, safety and efficacy, considerations for treatment selection, and combination treatment strategies.



Multidisciplinary Medication Management in ILD Care
Credits: 0.50 CME

In this discussion-based module, a panel of ILD experts in pulmonology and rheumatology explore the complexities of medication management for patients with ILD and the importance of multidisciplinary collaboration for optimal patient care.



Non-Pharmacologic Approaches to ILD Management
Credits: 0.25 CME

In this module, we explore non-pharmacologic approaches to management of ILD, including oxygen therapy, pulmonary rehabilitation, lung transplant, and palliative care.



Comorbidities of SARD-ILD




Pulmonary Hypertension in Rheumatologic Disease



Strategies for Multidisciplinary Collaboration in ILD Care

Online Modules: Level 1 Participation


Final Outcomes Summary



Designation	Total
MD/DO	53
NP	3
PA	6
RN	2
Other	5
Total Learners	69

Online Modules: Level 1 Participation

Final Outcomes Summary




Specialty	Total
Pulmonary	33
Rheumatology	11
Family Medicine / General Practice / Primary Care	13
Other	12
Total Learners	69

Online Modules: Level 2 Satisfaction

Final Outcomes Summary


Evaluation Respondents reported that the activity:



Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary

Overall Knowledge Gain across Video Modules



Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary

In the interim outcomes analysis, learners demonstrated high baseline knowledge at pre-test for many assessment items. At that time, program chairs reviewed all test questions to determine whether changes were needed to ensure rigor, quality and effectiveness in measuring achievement of the learning objectives. Revisions were made to the questions, which are reflected in the following slides.

Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary


Question 1: Which of the following best reflects the predominant classification strategy for interstitial lung diseases (ILDs) according to recent guidelines and consensus statements?

A) ILDs are classified by radiologic pattern into fibrotic (UIP versus non-UIP) and non-fibrotic types.

B) ILDs are classified into four major etiologic categories: idiopathic interstitial pneumonias, ILDs associated with connective tissue disease, ILDs related to environmental or occupational exposures and ILDs secondary to drugs or other known causes.

C) ILDs are classified based on pathologic diagnosis as UIP, NSIP, LIP, DIP, organizing pneumonia, granulomatous, or other unclassifiable pattern.

D) ILDs are classified based on the presence or absence of progression in fibrosis (progressive pulmonary fibrosis) using specific criteria using imaging, physiology, and patient reported symptoms.



Rationale:

The correct answer is B. This classification reflects the consensus in the medical literature, which emphasizes categorization by etiology—idiopathic, connective tissue disease—associated, exposure-related, and drug-induced or other known causes—as the foundation for clinical management and prognosis.

Module: Introduction to Interstitial Lung Disease (ILD)


Learning Objective: Describe the pathophysiology and classification of ILD

Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary

Question 2: Which of the following clinical findings is most characteristic of the initial presentation of interstitial lung disease (ILD)?

- A) Subacute chest discomfort, shallow breathing, and weight loss.
- B) Productive cough with fever but no acute infiltrates.
- C) Progressive exertional dyspnea and chronic dry cough**
- D) Wheezing or chest tightness and shortness of breath



Rationale:

The correct answer is C. Progressive exertional dyspnea and chronic dry cough are the most common presenting symptoms of ILD, often accompanied by fatigue and, in some cases, unintended weight loss. Physical examination may reveal bibasilar inspiratory crackles and, in advanced cases, digital clubbing or resting hypoxemia. These features are well described in the medical literature and are emphasized in recent reviews and guidelines on ILD clinical presentation.

Module: Introduction to Interstitial Lung Disease (ILD)


Learning Objective: Recognize signs, symptoms, and risk factors for ILD

Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary

Question 3: Which of the following high-resolution computed tomography (HRCT) findings is most indicative of progressive pulmonary fibrosis in a patient with fibrotic interstitial lung disease?

- A) New or increased ground-glass opacities with or without associated traction bronchiectasis
- B) Increased extent of traction bronchiectasis and honeycombing**
- C) Increased pleural thickening and lower lobe volume loss
- D) Reticulation and honeycombing that persists on prone imaging



Rationale:

The correct answer is B) Increased extent of traction bronchiectasis and honeycombing. Progressive pulmonary fibrosis is characterized radiographically by an increased extent of fibrotic features such as traction bronchiectasis, bronchiolectasis, and honeycombing, as well as increased reticulation and lobar volume loss. These findings are best appreciated by comparing serial HRCT scans for interval progression. The American Thoracic Society and collaborating societies emphasize that these features, particularly the progression of traction bronchiectasis and honeycombing, are strong predictors of disease progression and mortality in idiopathic pulmonary fibrosis and other fibrotic interstitial lung diseases.

Module: Progressive Pulmonary Fibrosis


Learning Objective: Recognize signs, symptoms, and risk factors for ILD

Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary

Question 4: Which of the following best reflects current best practices for monitoring patients with interstitial lung disease (ILD) for progressive pulmonary fibrosis (PPF) according to recent clinical guidelines?

- A) Chest radiograph and symptom assessment every 3-4 months
- B) Annual HRCT scans even in the absence of reported worsening in symptoms or PFT findings
- C) Pulmonary function tests (PFTs) including FVC and DLCO, symptom assessments, and HRCT when there is clinical suspicion of progression**
- D) Questionnaires assessing changes in cough or dyspnea every 6 months



Rationale:

The correct answer is C. Best practices for monitoring ILD patients for PPF involve a multimodal approach: regular assessment of symptoms, serial PFTs (notably FVC and DLCO) and HRCT imaging when there is evidence of clinical or physiological progression. Ambulatory desaturation testing (e.g., 6-minute walk test) may be considered as an adjunct, especially in patients with symptom progression. This approach is supported by the American Thoracic Society and the American College of Rheumatology, which recommend combining PFTs and HRCT for optimal monitoring, reserving HRCT for cases of clinical suspicion or uncertainty to balance diagnostic yield with radiation exposure. There is no consensus on the optimal frequency of HRCT, but more frequent monitoring is suggested for patients with worsening symptoms or rapidly progressive disease features.

Module: Progressive Pulmonary Fibrosis


Learning Objectives: Recognize signs, symptoms, and risk factors for ILD; Apply evidence-based diagnostic strategies to provide timely and accurate diagnosis of ILD

Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary

Question 5: A 58-year-old woman presents to your clinic with progressive dyspnea, dry cough, and crackles at the lung bases. HRCT shows NSIP pattern. You suspect an underlying autoimmune etiology. Which of the following laboratory tests is most appropriate to include in the initial serologic workup for SARD-ILD?

- A) B-type natriuretic peptide (BNP) and troponin
- B) ANCA and HIV serology
- C) ANA, RF/CCP, SSA/SSB, and myositis-specific antibodies**
- D) Alpha-1 antitrypsin levels and serum protein electrophoresis
- E) Sputum eosinophil count and IgE levels



Rationale:

The correct answer is C. Patients with suspected autoimmune-related ILD should undergo a targeted serologic evaluation that includes antinuclear antibody (ANA), rheumatoid factor (RF), anti-cyclic citrullinated peptide (CCP). Additional serologic panels including those for myositis-specific antibodies (e.g., anti-Jo-1, PL-7, MDA-5) and for systemic sclerosis are often performed. These biomarkers help identify underlying connective tissue diseases such as RA, Sjögren's disease, myositis, or systemic sclerosis. The other options are not routinely included in the initial evaluation for SARD-ILD.

Module: Recognizing SARD-ILD: Diagnosis and Screening

Learning Objectives: Apply evidence-based diagnostic strategies to provide timely and accurate diagnosis of ILD

Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary

Question 6: A 60-year-old man with systemic sclerosis-associated ILD shows evidence of progressive fibrosis on serial HRCT and declining FVC. He is currently receiving mycophenolate mofetil (MMF). According to current guidelines and clinical trial data, which of the following is the most appropriate next step?

- A. Discontinue MMF and switch to methotrexate
- B. Add antifibrotic therapy such as nintedanib**
- C. Initiate TNF- α inhibitor therapy
- D. Begin empiric corticosteroids as monotherapy
- E. Substitute MMF with hydroxychloroquine

■ Pre-Test (N=14)

■ Post-Test (N=9)

93%

89%

% Correct

This may represent a gap in knowledge and competence with regard to pharmacologic treatment strategies for ILD. Faculty focused the content of the second live virtual meeting on treatment strategies for CTD-ILD to address this need.

Rationale:

The correct answer is B. Nintedanib has shown benefit in slowing progression of fibrosis in SSc-ILD and is FDA approved for this indication. It can be used in combination with immunosuppressive therapy like MMF, as seen in the SENSICIS trial. Methotrexate and TNFi have limited or contraindicated roles in SARD-ILD due to potential pulmonary toxicity or lack of efficacy. Hydroxychloroquine is generally not sufficient for fibrosing ILD, and steroids alone are not the preferred treatment for progressive fibrosis.

Module: Pharmacologic Treatment of SARD-ILD: Lung-targeted Immunomodulatory and Anti-fibrotic Therapy


Learning Objectives: Apply up-to-date guidelines for the treatment of ILD

Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary

Question 7: A 64-year-old male with rheumatoid arthritis (RA) develops dyspnea and dry cough. Workup reveals ILD with mixed pattern of both organizing pneumonia and mild fibrosis on HRCT. Bronchoscopy rules out infection and identifies a lymphocytic alveolitis (41% on BAL). Current treatment is etanercept (TNF inhibitor) for joint disease which is currently well controlled. What is the best course of action for management of his new ILD?

- A. Inform the patient that in addition to RA he also now has IPF, and start nintedanib, an antifibrotic medication.
- B. Increase dosing of etanercept given that there is worsening lung inflammation, but also add nintedanib given the new finding of mild fibrosis.
- C. Coordinate a discussion between the patient's rheumatologist and pulmonologist to review the patient's new diagnosis of RA-related ILD and discuss therapeutic options to target both joint and lung inflammation. An antifibrotic could also be indicated.**
- D. Etanercept toxicity is the most likely cause of both lymphocytic alveolitis and lung fibrosis in this case. Stop the medication and monitor.



Rationale:

The correct answer is C. In this clinical scenario with new organizing pneumonia and mild fibrosis in the setting of known RA, the diagnosis is consistent with RA-ILD and once infection is ruled out, lung-targeted therapy is indicated to control inflammation. Combination therapy may be required. The patient's pulmonologist and rheumatologist should discuss options for the safest and most effective therapy. An antifibrotic could also be indicated, but active lung inflammation should be treated first. Etanercept is not effective in treating ILD in the setting of RA, so increasing the dose will not help. While there are case reports of ILD occurring due to lung toxicity of TNF-inhibitors like etanercept, the link is unclear and this is rare. The much more likely etiology of these imaging features is RA and alternative treatment will need to be started.

Module: Multidisciplinary Medication Management in ILD Care

Learning Objective: Implement multidisciplinary approaches for the early identification of and treatment of ILD

Online Modules: Level 3 & 4 Knowledge and Competence


Final Outcomes Summary

Question 8: A 65-year-old man with fibrotic ILD presents with increasing exertional dyspnea. He is already on antifibrotic therapy. A 6-minute walk test reveals oxygen desaturation to 85%. Which of the following non-pharmacologic interventions is the most appropriate next step?

- A. Begin supplemental oxygen therapy during exertion**
- B. Refer for pulmonary rehabilitation
- C. Initiate palliative care for symptom management
- D. Refer for lung transplant evaluation
- E. Recommend mindfulness-based stress reduction and routine exercise at home

Rationale:

The correct answer is A) Begin supplemental oxygen therapy during exertion. Oxygen desaturation to $\leq 88\%$ during a 6-minute walk test meets guideline-based criteria for initiating supplemental oxygen in ILD patients. While all listed options are valid components of a comprehensive non-pharmacologic approach, oxygen therapy is the most immediate and appropriate intervention for exertional desaturation. Pulmonary rehab and transplant referral may also be appropriate but are not as urgent in this context.



Module: Non-Pharmacologic Approaches to ILD Management

Learning Objective: Evaluate current and emerging approaches for ILD treatment;

Apply up-to-date guidelines for the treatment of ILD

Online Modules: Level 3 & 4 Knowledge and Competence


Final Outcomes Summary

Question 9: Which of the following statements is most accurate regarding atherosclerotic cardiovascular disease (ASCVD) in patients with SARD-ILD?

- A. Inflammation is now understood to contribute to ASCVD pathophysiology, therefore immunosuppressive therapies are indicated in those with known coronary disease.
- B. Aside from autoimmunity, patients with autoimmune disease have similar risk factors for ASCVD as those without autoimmunity.**
- C. Treadmill stress tests are less sensitive for the detection of CAD in patients with SARD-ILD relative to those without autoimmunity, therefore this test is not recommended in this population.
- D. LDL targets in SARD-ILD are comparable to those of patients with a known history of CVA or myocardial infarction.

Rationale:

Patients with autoimmune disease have an increased risk for atherosclerotic cardiovascular disease (ASCVD). A study of 85,512 patients with autoimmunity concluded that these patients have similar risk factors for CAD as the general population (Type 2 diabetes, hypertension, current smoking, elevated LDL-C of > 4 mmol/L and low HDL-C of <1mmol/L). This risk was accentuated by the presence of autoimmunity. There are no distinct guidelines for screening, diagnosing, or treating patients with ASCVD in the setting of autoimmunity as opposed to the general population. Therefore, answers a, c, and d are incorrect. Reference: Mortensen, MB et al, Association of Autoimmune Disease with Coronary Atherosclerosis Severity and Ischemic Events.



Module: Comorbidities of SARD-ILD


Learning Objective: Apply up-to-date guidelines for the treatment of ILD

Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary

Question 10: Which of the following statements best reflects the prevalence of pulmonary hypertension (PH) in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD)?

- A. PH is uncommon in CTD-ILD and usually presents only in advanced SLE.
- B. PH occurs almost exclusively in patients with both ILD and sleep apnea or nocturnal hypoxia.
- C. PH is common in CTD-ILD, with systemic sclerosis showing a prevalence of 5–19% for PAH**
- D. PH in CTD-ILD typically occurs only after immunosuppressive therapy has failed
- E. Due to high prevalence, routine screening for PH with right heart cath is recommended for patients with mixed connective tissue disease (MCTD)



Rationale:

The correct answer is C. Pulmonary hypertension is a common and serious complication of CTD-ILD, particularly in systemic sclerosis, where prevalence of pulmonary arterial hypertension (PAH) ranges from 5% to 19%. It may also be seen in other rheumatic conditions like SLE and MCTD. Routine screening is recommended in systemic sclerosis, and early recognition is critical due to its poor prognosis and distinct treatment implications.

Module: Pulmonary Hypertension in Rheumatologic Disease

Learning Objective: Recognize signs, symptoms, and risk factors for ILD

Online Modules: Level 3 & 4 Knowledge and Competence

Final Outcomes Summary

Question 11: A 58-year-old man with longstanding rheumatoid arthritis and RA-ILD presents to rheumatology clinic reporting worsening exertional dyspnea and oxygen requirement. He is already on rituximab. Joint disease is well controlled but recent pulmonary evaluation indicates a more rapid decline in oxygen on 6 min walk test, and fibrosis has continued to progress on imaging. The patient is currently enrolled in pulmonary rehab and has oxygen equipment at home. Which of the following would NOT be an appropriate consideration for management?

- A. Evaluation for comorbid pulmonary hypertension (PH). There is now therapy for ILD-related PH and this could offer an avenue for treatment.
- B. Referral to a tertiary care center for ILD for additional treatment recommendations and consideration of drug trials in ILD.
- C. Recommend discontinuation of exercise. Inform patient that he will need to limit exertion going forward so as to avoid episodes of oxygen desaturation.
- D. Discuss referral for lung transplant evaluation.
- E. Discuss adding immunosuppressant versus anti-fibrotic agent.
- F. A and E
- G. A, B and E**
- H. All of the above

■ Pre-Test (N=4)

■ Post-Test (N=3)

100%

100%

% Correct

Test-takers demonstrated high baseline knowledge of multidisciplinary ILD management strategies. Program chairs revised this question to better align with the learning objective.

Rationale:

The correct answer is G. This patient is a good candidate for further PH workup to see if this is a new aspect of their disease. They are also a good candidate for evaluation for ILD specific care, which could be completed by a Pulmonologist who is comfortable with ILD evaluation, or at an academic center. This patient is also a very good candidate for more aggressive therapeutic intervention with immunosuppressant versus anti-fibrotic or even combination therapy.

Module: Strategies for Multidisciplinary Collaboration in ILD Care

Learning Objective: Implement multidisciplinary approaches for the early identification and treatment of ILD

Online Modules: Level 4 Competence

Final Outcomes Summary

97%

Evaluation respondents intend to make changes in practice as a result of what they learned in the online modules

N=64

Changes that evaluation respondents intend to make in practice after participating in the modules:

- Closer follow up with the patient
- I will continue to refer pulmonary problem patients to specialists for treatment
- More thorough physical exams focused on extrapulmonary manifestations of SARD
- Incorporate specific labs
- Improve history taking
- PFT every 3 months in the first year of diagnosis, HRCT yearly
- Frequency of PFTs and ambulatory O2 monitoring
- High resolution CT
- Rheumatology referral pattern change based on single ANA alone
- Lab evaluation
- More specific use of serology workup
- More use of antifibrotic
- More multidisciplinary discussion
- Screen patients sooner for ILD and continue to refer when necessary
- Pay attention to comorbidities
- I will screen more aggressively for PH and referring to physicians currently in PH treatment

Live Virtual Meetings: Overview

Final Outcomes Summary

Live Virtual Meeting #1: Difficult Cases and Unmet Needs August 27, 2025



Zulma X. Yunt, MD
Associate Professor
Department of Medicine, Division of
Pulmonary, Critical Care & Sleep
Medicine, Clinic Director, Interstitial Lung
Disease Program, Medical Director,
Office of Professional Education
National Jewish Health



Barbara Goldstein, MD, MMSc
Physician
Denver Arthritis Clinic

**Collaborative ILD Live Discussion:
Challenging Diagnostic Cases**

Case 2

- 59 y/o M
- PMHx alcohol dependence, irritable bowel, insomnia
- Cough x 2 month in Nov 2024, treated with abx and 1 week steroids
- CT in Jan after cough returned – “linear atelectasis/scarring RML and RLL, LUL and lingula”.
- Progressive dyspnea x 3 months and started on O2 -> referred to pulm.
- No fevers, chills, weight loss or other systemic sx.
- Normal resting vitals. Fit appearing, no distress. Reduced lung volumes on exam but clear. Desaturated to 84% ambulating.
- HRCT and PFTs ordered.

Zulma X. Yunt, MD
Associate Professor
National Jewish Health

National Jewish Health

Live Virtual Meeting #2: Tailoring Treatment in CTD-ILD October 30, 2025



Joshua Solomon, MD
Director, Interstitial Lung Disease Program
Professor
Department of Medicine
Division of Pulmonary, Critical Care & Sleep
Medicine
Section of Critical Care Medicine
National Jewish Health



Melissa Griffith, MD, RhMSUS
Associate Professor of Medicine
Division of Rheumatology
University of Colorado School of
Medicine

How should we treat this patient?

What is our acute treatment?
What should he be on long term?
How frequently do we see him?

Participants:

- Josh Solomon
- Melissa Griffith
- NIH Professional Educ...
- Peter Riley
- Bruce Fitzgerald
- Barbara Goldstein
- Andrea Harshman
- Neil Sondhi
- Daniel Lifshen
- Sara Hahn
- Bruce Miller
- Shirley Brown
- Taylor Guess
- Claudia Moyer
- Mark Kearns
- Shu-Yi Liao
- ANA DOLORES...
- Nancy Davis
- Nicole Krupp
- Raymond Kraje...

Live Virtual Meetings: Overview

Final Outcomes Summary

Live Virtual Meeting #3: Diagnosing ILD: Patterns, Pitfalls, and Phenotypes January 13, 2026



Smarika Sapkota, MD, RhMSUS
Assistant Professor
Director, Rheumatology Clinic
Director, Ultrasound Clinic
Department of Medicine
Division of Rheumatology
National Jewish Health



Jeff Swigris, DO, MS
Professor
Department of Medicine
Division of Pulmonary, Critical
Care & Sleep Medicine
National Jewish Health

Rheum Teaching Points

- Recognizing early signs of systemic autoimmune rheumatic disease (SARD)-late onset Raynaud's, synovitis
- Identifying high risk patients for ILD - smoking history, older age and positive RNP
- Consider early screening for ILD among patients with risk factors
 - Recommended type of imaging – high-res CT chest with expiratory and inspiratory images (for screening as well as diagnosis purpose)
- Close collaboration with pulmonologist

Live Virtual Meeting #4: Combination Therapy in ILD: Practical Management Strategies March 10, 2026



Rebecca C. Keith, MD
Associate Professor
Department of Medicine
Division of Pulmonary, Critical Care & Sleep
Medicine
Interstitial Lung Disease Program
Autoimmune Lung Center
National Jewish Health



Mehnaz Maleki Fischbach, MD
Chief, Division of Rheumatology
Director, Scleroderma Center
Co-Director, Sjogren's Clinic
Professor
Department of Medicine
National Jewish Health

Collaborative ILD Live Discussion: Challenging Diagnostic Cases

Plan


- IV Cyclophosphamide
- Then back to Rituximab, mycophenolate, Nintedanib
- Lung transplant evaluation

	1/10/2024	2/10/2024	3/10/2024	4/10/2024	5/10/2024	6/10/2024	7/10/2024	8/10/2024	9/10/2024	10/10/2024	11/10/2024	12/10/2024	1/11/2024	2/11/2024	3/11/2024	4/11/2024	5/11/2024	6/11/2024	7/11/2024	8/11/2024	9/11/2024	10/11/2024	11/11/2024	12/11/2024	1/12/2024	2/12/2024	3/12/2024	4/12/2024	5/12/2024	6/12/2024	7/12/2024	8/12/2024	9/12/2024	10/12/2024	11/12/2024	12/12/2024	1/13/2025	2/13/2025	3/13/2025	4/13/2025	5/13/2025	6/13/2025	7/13/2025	8/13/2025	9/13/2025	10/13/2025	11/13/2025	12/13/2025	1/14/2026	2/14/2026	3/14/2026	4/14/2026	5/14/2026	6/14/2026	7/14/2026	8/14/2026	9/14/2026	10/14/2026	11/14/2026	12/14/2026	1/15/2027	2/15/2027	3/15/2027	4/15/2027	5/15/2027	6/15/2027	7/15/2027	8/15/2027	9/15/2027	10/15/2027	11/15/2027	12/15/2027	1/16/2028	2/16/2028	3/16/2028	4/16/2028	5/16/2028	6/16/2028	7/16/2028	8/16/2028	9/16/2028	10/16/2028	11/16/2028	12/16/2028	1/17/2029	2/17/2029	3/17/2029	4/17/2029	5/17/2029	6/17/2029	7/17/2029	8/17/2029	9/17/2029	10/17/2029	11/17/2029	12/17/2029	1/18/2030	2/18/2030	3/18/2030	4/18/2030	5/18/2030	6/18/2030	7/18/2030	8/18/2030	9/18/2030	10/18/2030	11/18/2030	12/18/2030	1/19/2031	2/19/2031	3/19/2031	4/19/2031	5/19/2031	6/19/2031	7/19/2031	8/19/2031	9/19/2031	10/19/2031	11/19/2031	12/19/2031	1/20/2032	2/20/2032	3/20/2032	4/20/2032	5/20/2032	6/20/2032	7/20/2032	8/20/2032	9/20/2032	10/20/2032	11/20/2032	12/20/2032	1/21/2033	2/21/2033	3/21/2033	4/21/2033	5/21/2033	6/21/2033	7/21/2033	8/21/2033	9/21/2033	10/21/2033	11/21/2033	12/21/2033	1/22/2034	2/22/2034	3/22/2034	4/22/2034	5/22/2034	6/22/2034	7/22/2034	8/22/2034	9/22/2034	10/22/2034	11/22/2034	12/22/2034	1/23/2035	2/23/2035	3/23/2035	4/23/2035	5/23/2035	6/23/2035	7/23/2035	8/23/2035	9/23/2035	10/23/2035	11/23/2035	12/23/2035	1/24/2036	2/24/2036	3/24/2036	4/24/2036	5/24/2036	6/24/2036	7/24/2036	8/24/2036	9/24/2036	10/24/2036	11/24/2036	12/24/2036	1/25/2037	2/25/2037	3/25/2037	4/25/2037	5/25/2037	6/25/2037	7/25/2037	8/25/2037	9/25/2037	10/25/2037	11/25/2037	12/25/2037	1/26/2038	2/26/2038	3/26/2038	4/26/2038	5/26/2038	6/26/2038	7/26/2038	8/26/2038	9/26/2038	10/26/2038	11/26/2038	12/26/2038	1/27/2039	2/27/2039	3/27/2039	4/27/2039	5/27/2039	6/27/2039	7/27/2039	8/27/2039	9/27/2039	10/27/2039	11/27/2039	12/27/2039	1/28/2040	2/28/2040	3/28/2040	4/28/2040	5/28/2040	6/28/2040	7/28/2040	8/28/2040	9/28/2040	10/28/2040	11/28/2040	12/28/2040	1/29/2041	2/29/2041	3/29/2041	4/29/2041	5/29/2041	6/29/2041	7/29/2041	8/29/2041	9/29/2041	10/29/2041	11/29/2041	12/29/2041	1/30/2042	2/30/2042	3/30/2042	4/30/2042	5/30/2042	6/30/2042	7/30/2042	8/30/2042	9/30/2042	10/30/2042	11/30/2042	12/30/2042	1/31/2043	2/31/2043	3/31/2043	4/31/2043	5/31/2043	6/31/2043	7/31/2043	8/31/2043	9/31/2043	10/31/2043	11/31/2043	12/31/2043	1/1/2044	2/1/2044	3/1/2044	4/1/2044	5/1/2044	6/1/2044	7/1/2044	8/1/2044	9/1/2044	10/1/2044	11/1/2044	12/1/2044	1/2/2045	2/2/2045	3/2/2045	4/2/2045	5/2/2045	6/2/2045	7/2/2045	8/2/2045	9/2/2045	10/2/2045	11/2/2045	12/2/2045	1/3/2046	2/3/2046	3/3/2046	4/3/2046	5/3/2046	6/3/2046	7/3/2046	8/3/2046	9/3/2046	10/3/2046	11/3/2046	12/3/2046	1/4/2047	2/4/2047	3/4/2047	4/4/2047	5/4/2047	6/4/2047	7/4/2047	8/4/2047	9/4/2047	10/4/2047	11/4/2047	12/4/2047	1/5/2048	2/5/2048	3/5/2048	4/5/2048	5/5/2048	6/5/2048	7/5/2048	8/5/2048	9/5/2048	10/5/2048	11/5/2048	12/5/2048	1/6/2049	2/6/2049	3/6/2049	4/6/2049	5/6/2049	6/6/2049	7/6/2049	8/6/2049	9/6/2049	10/6/2049	11/6/2049	12/6/2049	1/7/2050	2/7/2050	3/7/2050	4/7/2050	5/7/2050	6/7/2050	7/7/2050	8/7/2050	9/7/2050	10/7/2050	11/7/2050	12/7/2050	1/8/2051	2/8/2051	3/8/2051	4/8/2051	5/8/2051	6/8/2051	7/8/2051	8/8/2051	9/8/2051	10/8/2051	11/8/2051	12/8/2051	1/9/2052	2/9/2052	3/9/2052	4/9/2052	5/9/2052	6/9/2052	7/9/2052	8/9/2052	9/9/2052	10/9/2052	11/9/2052	12/9/2052	1/10/2053	2/10/2053	3/10/2053	4/10/2053	5/10/2053	6/10/2053	7/10/2053	8/10/2053	9/10/2053	10/10/2053	11/10/2053	12/10/2053	1/11/2054	2/11/2054	3/11/2054	4/11/2054	5/11/2054	6/11/2054	7/11/2054	8/11/2054	9/11/2054	10/11/2054	11/11/2054	12/11/2054	1/12/2055	2/12/2055	3/12/2055	4/12/2055	5/12/2055	6/12/2055	7/12/2055	8/12/2055	9/12/2055	10/12/2055	11/12/2055	12/12/2055	1/13/2056	2/13/2056	3/13/2056	4/13/2056	5/13/2056	6/13/2056	7/13/2056	8/13/2056	9/13/2056	10/13/2056	11/13/2056	12/13/2056	1/14/2057	2/14/2057	3/14/2057	4/14/2057	5/14/2057	6/14/2057	7/14/2057	8/14/2057	9/14/2057	10/14/2057	11/14/2057	12/14/2057	1/15/2058	2/15/2058	3/15/2058	4/15/2058	5/15/2058	6/15/2058	7/15/2058	8/15/2058	9/15/2058	10/15/2058	11/15/2058	12/15/2058	1/16/2059	2/16/2059	3/16/2059	4/16/2059	5/16/2059	6/16/2059	7/16/2059	8/16/2059	9/16/2059	10/16/2059	11/16/2059	12/16/2059	1/17/2060	2/17/2060	3/17/2060	4/17/2060	5/17/2060	6/17/2060	7/17/2060	8/17/2060	9/17/2060	10/17/2060	11/17/2060	12/17/2060	1/18/2061	2/18/2061	3/18/2061	4/18/2061	5/18/2061	6/18/2061	7/18/2061	8/18/2061	9/18/2061	10/18/2061	11/18/2061	12/18/2061	1/19/2062	2/19/2062	3/19/2062	4/19/2062	5/19/2062	6/19/2062	7/19/2062	8/19/2062	9/19/2062	10/19/2062	11/19/2062	12/19/2062	1/20/2063	2/20/2063	3/20/2063	4/20/2063	5/20/2063	6/20/2063	7/20/2063	8/20/2063	9/20/2063	10/20/2063	11/20/2063	12/20/2063	1/21/2064	2/21/2064	3/21/2064	4/21/2064	5/21/2064	6/21/2064	7/21/2064	8/21/2064	9/21/2064	10/21/2064	11/21/2064	12/21/2064	1/22/2065	2/22/2065	3/22/2065	4/22/2065	5/22/2065	6/22/2065	7/22/2065	8/22/2065	9/22/2065	10/22/2065	11/22/2065	12/22/2065	1/23/2066	2/23/2066	3/23/2066	4/23/2066	5/23/2066	6/23/2066	7/23/2066	8/23/2066	9/23/2066	10/23/2066	11/23/2066	12/23/2066	1/24/2067	2/24/2067	3/24/2067	4/24/2067	5/24/2067	6/24/2067	7/24/2067	8/24/2067	9/24/2067	10/24/2067	11/24/2067	12/24/2067	1/25/2068	2/25/2068	3/25/2068	4/25/2068	5/25/2068	6/25/2068	7/25/2068	8/25/2068	9/25/2068	10/25/2068	11/25/2068	12/25/2068	1/26/2069	2/26/2069	3/26/2069	4/26/2069	5/26/2069	6/26/2069	7/26/2069	8/26/2069	9/26/2069	10/26/2069	11/26/2069	12/26/2069	1/27/2070	2/27/2070	3/27/2070	4/27/2070	5/27/2070	6/27/2070	7/27/2070	8/27/2070	9/27/2070	10/27/2070	11/27/2070	12/27/2070	1/28/2071	2/28/2071	3/28/2071	4/28/2071	5/28/2071	6/28/2071	7/28/2071	8/28/2071	9/28/2071	10/28/2071	11/28/2071	12/28/2071	1/29/2072	2/29/2072	3/29/2072	4/29/2072	5/29/2072	6/29/2072	7/29/2072	8/29/2072	9/29/2072	10/29/2072	11/29/2072	12/29/2072	1/30/2073	2/30/2073	3/30/2073	4/30/2073	5/30/2073	6/30/2073	7/30/2073	8/30/2073	9/30/2073	10/30/2073	11/30/2073	12/30/2073	1/31/2074	2/31/2074	3/31/2074	4/31/2074	5/31/2074	6/31/2074	7/31/2074	8/31/2074	9/31/2074	10/31/2074	11/31/2074	12/31/2074	1/1/2075	2/1/2075	3/1/2075	4/1/2075	5/1/2075	6/1/2075	7/1/2075	8/1/2075	9/1/2075	10/1/2075	11/1/2075	12/1/2075	1/2/2076	2/2/2076	3/2/2076	4/2/2076	5/2/2076	6/2/2076	7/2/2076	8/2/2076	9/2/2076	10/2/2076	11/2/2076	12/2/2076	1/3/2077	2/3/2077	3/3/2077	4/3/2077	5/3/2077	6/3/2077	7/3/2077	8/3/2077	9/3/2077	10/3/2077	11/3/2077	12/3/2077	1/4/2078	2/4/2078	3/4/2078	4/4/2078	5/4/2078	6/4/2078	7/4/2078	8/4/2078	9/4/2078	10/4/2078	11/4/2078	12/4/2078	1/5/2079	2/5/2079	3/5/2079	4/5/2079	5/5/2079	6/5/2079	7/5/2079	8/5/2079	9/5/2079	10/5/2079	11/5/2079	12/5/2079	1/6/2080	2/6/2080	3/6/2080	4/6/2080	5/6/2080	6/6/2080	7/6/2080	8/6/2080	9/6/2080	10/6/2080	11/6/2080	12/6/2080	1/7/2081	2/7/2081	3/7/2081	4/7/2081	5/7/2081	6/7/2081	7/7/2081	8/7/2081	9/7/2081	10/7/2081	11/7/2081	12/7/2081	1/8/2082	2/8/2082	3/8/2082	4/8/2082	5/8/2082	6/8/2082	7/8/2082	8/8/2082	9/8/2082	10/8/2082	11/8/2082	12/8/2082	1/9/2083	2/9/2083	3/9/2083	4/9/2083	5/9/2083	6/9/2083	7/9/2083	8/9/2083	9/9/2083	10/9/2083	11/9/2083	12/9/2083	1/10/2084	2/10/2084	3/10/2084	4/10/2084	5/10/2084	6/10/2084	7/10/2084	8/10/2084	9/10/2084	10/10/2084	11/10/2084	12/10/2084	1/11/2085	2/11/2085	3/11/2085	4/11/2085	5/11/2085	6/11/2085	7/11/2085	8/11/2085	9/11/2085	10/11/2085	11/11/2085	12/11/2085	1/12/2086	2/12/2086	3/12/2086	4/12/2086	5/12/2086	6/12/2086	7/12/2086	8/12/2086	9/12/2086	10/12/2086	11/12/2086	12/12/2086	1/13/2087	2/13/2087	3/13/2087	4/13/2087	5/13/2087	6/13/2087	7/13/2087	8/13/2087	9/13/2087	10/13/2087	11/13/2087	12/13/2087	1/14/2088	2/14/2088	3/14/2088	4/14/2088	5/14/2088	6/14/2088	7/14/2088	8/14/2088	9/14/2088	10/14/2088	11/14/2088	12/14/2088	1/15/2089	2/15/2089	3/15/2089	4/15/2089	5/15/2089	6/15/2089
--	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	------------	------------	------------	-----------	-----------	-----------	-----------	-----------	-----------

Live Virtual Meetings: Level 1 Participation (All Meetings)

Final Outcomes Summary


Degree



69%
of learners in the live meetings were physicians and APPs

Degree	
MD	74
NP	5
PA	5
PharmD	6
RN	15
Other	16
Total Learners	121

Specialty




63%
of learners in the live meetings were in pulmonology and rheumatology

Specialty	
Pulmonology	65
Rheumatology	11
Family Medicine	8
Internal Medicine	9
Not Reported	1
Other	27
Total Learners	121

Live Virtual Meetings: Level 2 Satisfaction (Combined Webinar Evaluation)

Final Outcomes Summary

Evaluation Respondents reported that the activity:



N=35




Live Virtual Meetings: Level 4 Competence (Meeting #1)

Final Outcomes Summary

Evaluation respondents report they are “Very Confident” to “Somewhat Confident” in their ability to complete a comprehensive diagnostic evaluation for patients with suspected ILD

Live Virtual Meeting #1: Difficult Cases and Unmet Needs




Live Virtual Meetings: Level 4 Competence (Meeting #2)

Final Outcomes Summary

Evaluation respondents report they are “Very Confident” to “Somewhat Confident” in their ability to select individualized treatment strategies for patients with CTD-ILD

Live Virtual Meeting #2:




Live Virtual Meetings: Level 4 Competence (Meeting #3)

Final Outcomes Summary

Evaluation respondents report they are “Very Confident” to “Somewhat Confident” in their ability to diagnose and classify ILD

Live Virtual Meeting #3: Diagnosing ILD: Patterns, Pitfalls, and Phenotypes




Live Virtual Meetings: Level 4 Competence (Meeting #4)

Final Outcomes Summary

Evaluation respondents report they are “Very Confident” to “Somewhat Confident” in their ability to use combination therapy to treat patients with ILD

Live Virtual Meeting #4: Combination Therapy in ILD: Practical Management Strategies



Live Virtual Meetings: Level 4 Competence (All meetings)

Final Outcomes Summary

93%

**Evaluation
respondents intend
to make changes in
practice as a result
of the activity**

N=28

Changes that evaluation respondents intend to make in practice after participating in the live virtual meetings:

- Diagnosis and therapy
- More confidence around Rx
- Rheum medication options
- More likely to prescribe nintedanib in PPF patients with bleeding risk factors with shared decision making
- Being mindful of side effects of nintedanib.
- Considering cellcept or rituximab + nintedanib
- Send autoimmune patients to pulmonary clinic if they have respiratory symptoms (for pulmonary care)
- Ensuring I am reviewing every CT scan I can and not going off of the radiologist read alone
- To have a better understanding of NSIP
- Collaborate with pulmonary

Community Forum

Final Outcomes Summary

In patients with rapidly-progressive ILD with high suspicion for anti-MDA5, the ACR guidelines conditionally recommend up-front triple therapy. This includes pulse IV steroids with 2 additional therapies (options include rituximab, cyclophosphamide, IVIG, mycophenolate, calcineurin inhibitor, and JAK inhibitor). Of these options, what therapies do you typically prefer? Any specific factors that you take into account?



Reply



What is your approach to management of new onset symptomatic ILD in a patient with RA who is otherwise well controlled joint wise on methotrexate or leflunomide?



Reply



4,104+ views on the Community Forum!

Fascinating, but as far as I know we don't yet have any info. Clinically, we are using Otezla in practice for psoriatic arthritis. I find that it's a good drug for mild to moderate disease. Patient side effects are an issue for some and that can be an issue. What has been so helpful is that it's not immunosuppressing. So I use it as monotherapy or in combination with other agents.



Reply



Vivianne Allsop MD Topic starter

(@a11sopv) Active Member Joined: 6 months ago

Jan 07, 2026 3:02 pm



Posts: 3

I have a 34-year-old patient with a positive MDA 5 antibody (2x upper limit of normal) that was checked in the setting of nonspecific, fibromyalgia-like symptoms. She currently has normal PFT's, HRCT chest, TTE, muscle enzymes, and no rashes or synovitis. How would you approach screening for ILD development in patients with an incidental high-risk antibody like MDA-5 or SCL-70 but no current systemic manifestations?



Reply

2 REPLIES



Rebecca Keith MD (Pulmonology) Admin


(@keithre) Member Joined: 10 months ago

Posts: 3

We do know that patients with MDA5 positive antibody and ILD can have rapidly progressive disease. We do not know what the incidence of MDA 5 is in the absence of disease and what to do about it. I would likely see back in 1 year for a re-evaluation or sooner if any symptoms. Would also recommend age-appropriate cancer screening. Any other opinions out there?



Reply



60 posts on the Community Forum!

Example Questions in the ILD Discussion Forum

- Discussed a case today about a patient that presented with respiratory distress. Found to have lung consolidations. Had hemoptysis and transferred to the ICU. Bronchoscopy revealed diffuse alveolar hemorrhage on 3 serial lavages. What would your work-up be for causes?
- What are your current strategies for coordinating ILD care between rheumatology and pulmonology in your practice?
- What is your approach to selecting immunosuppressive therapy for patients with both arthritis and ILD?

Level (5) Outcomes: Performance

Final Outcomes Summary

45-day follow-up survey respondents report the impact of the activity on their practice (N=8)

While the response rate to the follow-up survey was low with only eight respondents, their responses indicate that participation in the activity has made a positive impact on their practice and their patients.

How many patients do you see per week affected by conditions discussed in this activity?




20 or more patients

11-19 patients

5-10 patients

1-4 patients



6 out of 7 reported that the activity helped address barriers in their practice.


Barriers still faced include:

- Lack of familiarity with diagnostic and/or treatment guidelines
- Uncertainty in treatment selection
- Limited access to multidisciplinary care
- Insurance/access barriers

Level (5) Outcomes: Performance

Final Outcomes Summary

45-day follow-up survey respondents report the impact of the activity on their practice (N=8)



Examples of changes made in practice


- Incorporated new information into patient encounters.
- Being less reluctant to due multimodal treatment of ILD
- Screening and monitoring for ILD
- I am now more familiar with the latest treatment strategies.

Level (5) Outcomes: Performance


Final Outcomes Summary

Upon registration, participants were asked about their confidence in ILD diagnosis and management to get a baseline. Post-program confidence data was collected 45 days after the pilot program ended.

How confident are you in your ability to identify early signs of ILD in your patient population?
(Percentage of respondents that answered somewhat-very confident)



Which best describes your familiarity with current ILD diagnostic and treatment guidelines?
(Percentage of respondents that answered somewhat-very familiar)



Learners who participated in the program demonstrated significant gains in confidence.

Overall Program: Evaluation Results

Final Outcomes Summary



Key Takeaways

- The connection to arthritic and autoimmune disease.
- That more specific ILD diagnosis improves treatment selection
- The diagnostic algorithm for ILD
- ILD pattern on CT
- Differentiating the type of ILD
- The importance of collaboration with rheumatology colleagues
- Diagnose early and screen aggressively in high-risk patients. Combination therapy appropriate and continued expansion of treatment options via biologic therapies
- Need multidisciplinary care
- Screening early for ILD



Future Topics

- HP
- GI
- GERD
- Nutrition
- New research

Barriers Addressed

- Cost / Insurance
- antifibrotics and coverage
- Antifibrotic barriers
- The hurdles with obtaining Pirfenidone in PPF
- Referral to other specialties
- Prior authorization

Program Insights

Final Outcomes Summary

- This pilot program more than doubled its participation goal, engaging 176 physicians and 274 total learners, with 67% of participants representing pulmonology or rheumatology. This reach demonstrates considerable demand for longitudinal, multidisciplinary ILD education.
- Among the 45-day follow-up survey respondents, confidence in identifying early signs of ILD increased from 65% to 100%, and familiarity with current diagnostic and treatment guidelines increased from 63% to 100%. In addition, 75% reported already applying new knowledge in practice. These data provide encouraging evidence of continued practice impact.
- The community forum generated more than 4,100 views, despite no credit being claimed for forum participation, suggesting that access to peer and expert exchange was valuable to learners. Feedback suggests that future programs should consider a mobile-friendly platform or app to make participation more convenient and sustain engagement.

"I liked that the program was multifaceted - you could choose various platforms for education. The forum and videos were available anytime, which fits busy schedules nicely. The live meetings were engaging and while less convenient in terms of scheduling, they offered an opportunity for interaction with field experts.

This program spanned a 10-month period which I felt was a strength; it was available to revisit. I feel this is important for the sake of building community."

– Zulma Yunt, MD, Program Chair

Accreditation

Interim Outcomes Summary

National Jewish Health is accredited with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The NJH Office of Professional Education produced and accredited this program and adhered to the updated ACCME guidelines.

National Jewish Health designates the live and enduring activities for a maximum of 10.0 *AMA PRA Category 1 Credits*™ and 10.0 ABIM MOC points.

